Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin
publication date: May 10, 2022
Tonghua Dongbao Pharma has dosed the first person in a China Phase III trial of an Ultra-Rapid insulin developed by Adocia of Lyon, France. The trial will enroll 1300 people with type 1 and type 2 diabetes in 100 China sites. As part of a two-drug deal,, Tonghua Dongbao in-licensed China and South-East Asia rights to BioChaperone® Lispro from Adocia for $10 million upfront and $35 million in milestones, plus royalties. The second Adocia diabetes therapy in the deal is a fixed-ratio glargine and lispro combination. More details....
Stock Symbols: (SHA: 600867) (Paris: ADOC)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.